Organization
Philadelphia, PA
64 abstracts
Abstract
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA,
Abstract
A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).Org: University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Effects of immune-enhancing nutrition on radical cystectomy outcomes: Primary results from the randomized phase III double-blind clinical trial (S1600).Org: University of Kansas Medical Center, Kansas City, KS, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA,
Abstract
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.Org: Gustave Roussy Cancer Center, Université Paris Saclay, Paris, France, Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science,
Abstract
Multi-site randomized trial of stepped palliative care (PC) for patients with advanced lung cancer.Org: Massachusetts General Hospital, Division of Hematology and Oncology/Department of Medicine, Boston, MA, Harvard Medical School, University of Pennsylvania,
Abstract
BE-a-PAL: A cluster-randomized trial of algorithm-based default palliative care referral among patients with advanced cancer.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Perelman School of Medicine at the University of Pennsylvania, Tennessee Oncology, PLLC,
Abstract
National survey of patient perspectives on medication costs among co-pay assistance recipients with cancer.Org: University of Oklahoma Health Sciences Center, Oklahoma City, Okyo Pharma, Fox Chase Cancer Center, Philadelphia, PA,
Abstract
Impact of protein energy malnutrition on hospitalized patients with lung cancer: A United States population-based cohort study.Org: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Jefferson-Einstein Hospital, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Albert Einstein Healthcare Network, Philadelphia, PA,
Abstract
ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis.Org: Exact Sciences Corporation, Genomic Health Inc, Fred Hutchinson Cancer Research Center, Tisch Cancer Institute, Fox Chase Cancer Center,
Abstract
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, Cancer Research and Biostatistics, University of Kansas Medical Center, ASCO,
Abstract
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.Org: University of California, San Diego Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Winship Cancer Institute of Emory University,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells.Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Center for Cellular Immunotherapies, Department of Biostatistics, Epidemiology, and Informatics,
Abstract
A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group.Org: University of Chicago Medical Center, Chicago, IL, Children's Oncology Group Statistics and Data Center, University of Florida, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Children's Oncology Group Statistics & Data Center, Department of Biostatistics & Data Science,
Abstract
Uptake of germline cancer genetic services in a randomized trial of remote telehealth services as compared to usual care: A report from the Childhood Cancer Survivor Study (CCSS).Org: University of Chicago Pritzker School of Medicine, Fox Chase Cancer Center, University of Pennsylvania, Columbia University Mailman School of Public Health, New York, NY, Duke University Medical Center,
Abstract
Randomized trial of a multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HSCT) survivors.Org: Massachusetts General Hospital, Fox Chase Cancer Center, Lifespan Cancer Institute, Dana-Farber Cancer Institute/Mass General Brigham, Division of Hematology and Oncology/Department of Medicine,
Abstract
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).Org: Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, Duke University Medical Center/Duke Cancer Institute,
Abstract
Site versus central read discrepancy rates in PCWG3 evaluation for progression.Org: Clario, Philadelphia, PA, PainReform,
Abstract
Trends and landscape of clinical outcome assessment use to support oncology product approvals.Org: Clario, Philadelphia, PA, PainReform,
Abstract
OncoGPT: Enhancing oncological decision-making with ASCO guideline–trained AI.Org: The Ohio State University - James Cancer Hospital, Columbus, OH, Thomas Jefferson University, Philadelphia, PA,
Abstract
Does sidedness predict risk of perforation with chemotherapy in colon cancer? Results from the National Inpatient Samples Database (NISD).Org: Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Philadelphia, PA, University of Massachusetts Chan Medical School, Worcester, MA,
Abstract
Dynamic machine learning model to forecast patient availability for clinical trials.Org: ConcertAI, Cambridge University Hospitals NHS Foundation Trust, Bengaluru, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,
Abstract
Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer.Org: Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Philadelphia, PA, National Cancer Center Hospital East, Kashiwa, Japan, Shinjuku-Ku, Japan,
Abstract
Saturation genome editing-based functional evaluation and clinical classification of BRCA2 single nucleotide variants.Org: Department of Laboratory Medicine and Pathology, University of Washington, Mayo Clinic, Rochester Regional Health System, MN, Ambry Genetics,
Abstract
Recruiting Black and White patients to a behavioral oncology clinical trial: Lessons from the DISCO trial.Org: Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, Wayne State University, Karmanos Cancer Center,
Abstract
The factors associated with all-cause in-hospital mortality in patients with malignant well-differentiated gastroenteropancreatic neuroendocrine tumors: A retrospective analysis of National Inpatient Survey (NIS) 2020 dataset.Org: Internal Medicine Residency, Jefferson-Einstein Hospital, Philadelphia, PA, PainReform, Johns Hopkins University Bloomberg School of Public Health,
Abstract
Real world tebentafusp-tebn experience at a tertiary care referral center.Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University, Philadelphia, PA,
Abstract
Patient- and clinician-directed implementation strategies to improve serious illness communication for high-risk patients with cancer: A cluster-randomized pragmatic trial.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, School of Nursing, University of Alabama at Birmingham, Birmingham, AL, Mailman School of Public Health, Columbia University,
Abstract
Assessment of electronic health record (EHR) –based machine learning (ML) in predicting risk of brain metastasis among patients with early-stage non–small-cell lung cancer (eNSCLC).Org: ConcertAI, Cambridge University Hospitals NHS Foundation Trust, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,
Abstract
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.Org: School of Medicine, Zhejiang University, Hangzhou, China, Yale University, New Haven, CTI BioPharma, Keck School of Medicine of the University of Southern California,
Abstract
Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE).Org: University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA, University of Pennsylvania, Hospital of the University of Pennsylvania, Univ of Pa,
Abstract
Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Boston, MA, Stephenson Cancer Center University of Oklahoma/Sarah Cannon Research Institute, Oklahoma City, OK,
Abstract
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).Org: Gustave Roussy and Paris Saclay University, Villejuif, France, Faculty of Medicine, Cairo University, Villejuif / Kremlin-Bicêtre, France, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine,
Abstract
Completion rates and trends of the patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) across 14 oncology clinical trials.Org: Clario, Philadelphia, PA,
Abstract
Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial.Org: Dana-Farber Cancer Institute, Boston, MA, Brigham and Women's Hospital/Massachusetts General Hospital, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,
Abstract
A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.Org: Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Ulsan University Hospital, Ulsan, South Korea,
Abstract
Hospital Anxiety and Depression Scale (HADS) score trends among testicular cancer survivors: A longitudinal study.Org: University of Pennsylvania, Philadelphia, PA, PainReform,
Abstract
Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study.Org: Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, Yale Cancer Center, Yale School of Medicine, New Haven, CT, New Haven, CT,
Abstract
Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).Org: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, New Brunswick, Roswell Park Comprehensive Cancer Center, Buffalo, IL, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Differences in perceptions and use of remote patient monitoring technology in rural cancer programs.Org: Penn State Health Milton S. Hershey Medical Center, Hershey, PA, Association of Community Cancer Centers (ACCC), Rockville, MD, Rockville, MD, Rhizome, LLC,
Abstract
Phase II trial of consolidation pembrolizumab (pembro) after proton reirradiation (re-RT) for thoracic recurrences of non-small cell lung cancer (NSCLC).Org: University of Pennsylvania, Philadelphia, PA, PainReform, CVS Health, Perelman School of Medicine,
Abstract
The impact of neoadjuvant chemotherapy on 30-day radical cystectomy outcomes.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Sidney Kimmel Medical College of Thomas Jefferson University, Thomas Jefferson University, Philadelphia, PA, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.Org: Hillman Cancer Center, Pittsburgh, PA, Pittsburgh, PA, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Boston, MA, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
Racial disparities in the prevalence of extrathoracic metastases in lung cancer patients and survival: A SEER database study (2010–2019).Org: Seidman Cancer Center, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, Cleveland, OH, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
Associations of loneliness and mortality risk among cancer survivors in the United States.Org: American Cancer Society, Atlanta, GA, Fox Chase Cancer Center, Philadelphia, PA,
Abstract
Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.Org: Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, Fox Chase Cancer Center, Temple University Health System,
Abstract
Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, University of Colorado Denver Anschutz Medical Center, Aurora, CO,
Abstract
A novel program to address acute food insecurity among patients with cancer in Philadelphia.Org: Legacy of Hope, Philadelphia, PA, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center at Thomas Jefferson University, Sidney Kimmel Medical College at Thomas Jefferson University,
Abstract
The impact of portability of wearable monitoring device on study retention and participant experience in patients with unresectable stage III NSCLC treated with standard-of-care durvalumab: Learnings from the ON TRAX pilot study.Org: AstraZeneca, Gaithersburg, MD, MD Anderson Cancer Center, Current Health, Boston Pharmaceuticals,
Abstract
A pilot, open study to assess efficacy and safety of ON-01910 (rigosertib) in patients with recessive dystrophic epidermolysis bullosa associated locally advanced/metastatic squamous cell carcinoma.Org: Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, Jefferson Clinical Research Institute, Onconova Therapeutics,
Abstract
The role of micro-CT for intraoperative margin assessment of breast cancer.Org: Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of),
Abstract
Trends and survival of malignant mesothelioma across racial groups between 2000-2019: A real-world study.Org: Seidman Cancer Center, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, Cleveland, OH, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,
Abstract
Celiac plexus radiosurgery for pain management in advanced cancer: An international phase II trial, health-related quality of life (HRQOL) outcomes.Org: Sheba Medical Center, Or-Yeuda, Ramat Gan, Israel, Israeli Medical Research Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice,
Abstract
Effect of microRNA-21 blockade in human triple negative breast cancer allografts on progression and immune checkpoint proteins.Org: Bound Therapeutics LLC, Cherry Hill, NJ, Thomas Jefferson University, Philadelphia, PA, Bio-Synthesis, Inc.,
Abstract
Falls and hospitalization during chemotherapy in older women with early breast cancer.Org: City of Hope National Medical Center, Duarte, CA, University of Nebraska Medical Center, Omaha NE, Neurocentria,
Abstract
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Outcomes with bendamustine lymphodepletion prior to brexucabtagene autoleucel for mantle cell lymphoma.Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA,
Abstract
Does low-grade follicular lymphoma with high proliferation index require a different treatment strategy? A single center experience.Org: Allegheny General Hospital, Pittsburgh, PA, Allegheny Health Network Cancer Institute, Philadelphia College of Osteopathic Medicine, Philadelphia, PA,
Abstract
Disparities in the recommendation, acceptance, and performance of surgery as treatment modality for patients with stage 0-III breast cancer.Org: Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA,
Abstract
HLA discordance between blood and tumor: A treatment conundrum?Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University, Philadelphia, PA,
Abstract
A retrospective chart review of palliative care consultation during curative-intent chemoradiation for head and neck cancer.Org: Temple University Hospital, Philadelphia, PA, Philadelphia, PA, Perelman School of Medicine, Fox Chase Cancer Center, Beth Israel Deaconess Medical Center,
Abstract
BELIMUMAB IN PAEDIATRIC SLE (THE PLUTO STUDY) – STUDY DESIGN AND PARTICIPATION Org: GSK Research and Development Upper Providence, Collegeville, PA, Philadelphia, PA, United States Army Research Institute of Environmental Medicine,
Abstract
Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkersOrg: University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, UK University Hospital Gasthuisberg, Leuven Cancer Institute, Belgium Botnar Research Centre,